Product Description
XmAb7195 is a monoclonal antibody engineered to suppress IgE via three distinct mechanisms of action as a potential treatment for asthma and other atopic disease.
Mechanisms of Action: IgE Binder
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Xencor
Company Location: Western America
Company CEO: Bassil I. Dahiyat
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Healthy Volunteers|Rhinitis, Allergic|Dermatitis, Atopic|Conjunctivitis, Allergic
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02881853 |
XmAb7195-02 | P1 |
Completed |
Healthy Volunteers |
2017-02-24 |
2019-03-20 |
Treatments |
|
NCT02148744 |
XmAb7195-01 | P1 |
Completed |
Rhinitis, Allergic|Conjunctivitis, Allergic|Dermatitis, Atopic |
2015-09-21 |
2019-03-20 |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
02/27/2020 |
News Article |
Aimmune Therapeutics Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Recent Operational Highlights |
|
02/24/2020 |
News Article |
Xencor Reports Fourth Quarter and Full Year 2019 Financial Results |
|
02/05/2020 |
News Article |
Aimmune Licenses Exclusive Worldwide Rights to Xencor's XmAb®7195 for the Development of Next-Generation Food Allergy Treatments |
|
02/05/2020 |
News Article |
Aimmune Licenses Exclusive Worldwide Rights to Xencor's XmAb®7195 for the Development of Next-Generation Food Allergy Treatments |